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Summary
Bisphosphonates are a class of agents used to treat osteo-
porosis and malignant bone metastases. Despite these bene-
fits, osteonecrosis of the jaws has recently emerged as a sig-
nificant complication in a subset of patients receiving these
drugs. Based on a growing number of case reports and insti-
tutional reviews, bisphosphonate therapy may cause exposed
and necrotic bone that is isolated to the jaw. This complica-
tion usually presents following simple dentoalveolar surgery
and can cause a significant adverse effect on the quality of
life for most patients. The pathogenesis for this complication
appears to be related to the profound inhibition of osteoclast
function and bone remodeling. This report will review the
clinical signs and symptoms and risks associated with this
new complication and provide a guideline for establishing a
stage-specific diagnosis of BRONJ. 
KEY WORDS: bisphosphonate-related osteonecrosis of the jaw, BRONJ,
bisphosphonate associated osteonecrosis of the jaw, bisphosphonate, os-
teonecrosis of the jaw.
Introduction
Bisphosphonates are a class of agents used to treat osteoporo-
sis and the complications associated with malignant bone
metastases. Their use has dramatically increased over the past
few years as new indications for their use have arisen. Bisphos-
phonate therapy has made a significant impact in the palliation of
cancer morbidity. Their role in decreasing osteoclast-mediated
lysis of bone in disease secondary to multiple myeloma, breast
cancer and other solid tumors has been well established in clini-
cal trials (1, 2). The efficacy of intravenous bisphosphonates in
reducing bone pain, hypercalcemia and skeletal complications
has been extensively documented in patients with advanced
breast cancer and multiple myeloma (3-8). Thus bisphospho-
nates are frequently administered to patients with osteolytic
metastases, especially if there is risk for significant morbidity.
Based on clinical practice guidelines established by the Ameri-
can Society of Clinical Oncology, the use of bisphosphonates is
considered the standard of care for treatment of: 1) moderate to
severe hypercalcemia associated with malignancy; and 2)
metastatic osteolytic lesions associated with breast cancer and
multiple myeloma in conjunction with antineoplastic chemothera-
peutic agents (9, 10).
As potent suppressors of osteoclast activity, bisphosphonates
slow the remodeling process and increase bone mineral density
thereby reducing the risk of fracture in women with osteopenia
and osteoporosis (11, 12). All bisphosphonates currently ap-
proved for osteoporosis treatment have been shown to signifi-
cantly reduce the risk of osteoporotic fractures. Alendronate has
been shown to prevent bone loss at the spine and hip in
menopausal women and reduce fractures at these sites by ap-
proximately 50% (13-15). In a large prospective trial, risedronate
produced a 30% reduction in hip fractures (16, 17). Due to their
proven clinical efficacy, bisphosphonates are considered first-
line therapy in the treatment of osteoporosis and are the most
widely prescribed antiresorptive agent.
Despite these benefits, osteonecrosis of the jaws has recently
emerged as a significant complication in a subset of patients re-
ceiving these drugs. Based on a growing number of case reports
and institutional reviews, bisphosphonate therapy may cause ex-
posed and necrotic bone that is isolated to the jaw. 
Since 2003 numerous reports have been published highlighting
the adverse effect profile of this class of agents including the de-
velopment of osteonecrosis of the jaw in patients treated with
bisphosphonates (18-31). Although the exact mechanism of bis-
phosphonate-induced osteonecrosis of the jaw (BRONJ) has not
yet been determined, several hypotheses have been proposed.
In most cases the pathogenesis of this process is consistent with
a defect in jawbone physiologic remodeling or wound healing.
The profound inhibition of osteoclast function can also inhibit
normal bone turnover to an extent that local micro damage from
normal mechanical loading or injury (tooth extraction) cannot be
repaired. Alternatively, the antiangiogenic properties of bisphos-
phonates may affect the local bone blood supply contributing to
the apparent ischemic changes noted in the affected patients’
jawbones. Since only a minority of bisphosphonate users devel-
op bone necrosis, it is also possible that individual genetic varia-
tions in drug metabolism or skeletal homeostasis may confer
susceptibility or resistance to developing BRONJ. 
The apparent selective involvement of the maxilla and mandible
may be a reflection of the unique environment of the oral cavity.
Typically, healing of an open bony wound (e.g. extraction sock-
et) in the presence of normal oral micro flora occurs quickly and
without complication. However, when the healing potential of the
mandible or maxilla is compromised either by tumoricidal radia-
tion doses or some other agent(s) or pathologic process; then
minor injury or disease in these sites increases risk for os-
teonecrosis and possible secondary osteomyelitis. Also, bispho-
sphonates are preferentially deposited in bones with high
turnover rates; given that the maxilla and mandible are sites of
significant bone remodeling, it is possible that the levels of bis-
phosphonate within the jaw are selectively elevated. It is interest-
ing to note that to date this complication has not been reported
within bones outside the craniofacial skeleton. 
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Mini-review
Several retrospective clinical studies have identified potential risk
factors associated with the development of BRONJ (32-40).
These include a history of dentoalveolar trauma, duration of bis-
phosphonate exposure and the type of bisphosphonate. In the
majority of BRONJ cases reported to date, recent dentoalveolar
trauma was the most prevalent and consistent risk factor (24, 38,
39). Patients with a history of inflammatory dental disease, e.g.,
periodontal and dental abscesses, are at a seven-fold increased
risk for developing BRONJ (41). This underscores the impor-
tance of maintaining good oral health and avoiding extractions in
this population. The duration of bisphosphonate therapy also ap-
pears to be related to the likelihood of developing necrosis with
longer treatment regimens associated with a greater risk of de-
veloping disease (38, 41). In addition, the more potent intra-
venous bisphosphonates, such as pamidronate and especially
zolendronate, appear to be significantly more problematic as
compared with the oral bisphosphonate medications. Initially,
BRONJ was seen only with the use of the more potent intra-
venous forms of the drug, however, their have been reports of
osteonecrosis in patients on the less potent oral forms (20, 24,
42). This alarming finding may have significant implications as
the number of patients on oral bisphosphonates increases.
Though found in both sexes, the literature reports more cases of
BRONJ in females than males which is likely a reflection of the
large number of cases reported in breast cancer patients. With
postmenopausal osteoporosis as an indication for bisphospho-
nate use, a large percentage of the female population may also
be at risk for developing BRONJ. Patients receiving oral bispho-
sphonate therapy for osteoporosis that develop BRONJ have
typically been exposed to these agents for a longer period of
time (greater than 3 years) or were also exposed to steroid ther-
apy (43). 
Current incidence data for BRONJ are limited to retrospective
studies with limited sample sizes. The current difficulty in estab-
lishing exact incidence data is due to several factors which in-
clude a non-standardized definition and inconsistencies in case
recognition and reporting. With that understanding, the estimate
of cumulative incidence of BRONJ in patients receiving intra-
venous bisphosphonates for malignant disease ranges from
0.8%-12% (43). For those patients exposed to oral bisphospho-
nates, the incidence appears to be significantly less (43). 
In 2005 the Food and Drug Administration responded to the
growing number of BRONJ cases by issuing broad drug class
warning of this complication for all bisphosphonates.
This has also prompted a change in clinical practice. With the
benefit of bisphosphonate therapy beyond 5 years coming into
question for patients with low to moderate risk of an osteoporotic
fracture (44, 45) and the growing concern about long-term sup-
pression of bone turnover (46, 47), some clinicians have empha-
sized the importance of a drug holiday. Bisphosphonate treat-
ment algorithms for the oncology patient have been modified in
some institutions as well. In a consensus statement from the
Mayo Clinic, the use of bisphosphonates in the treatment of mul-
tiple myeloma was modified to limit the exposure of intravenous
bisphosphonates and minimize the potential for developing
BRONJ (48). The efficacy of these new treatment strategies in
decreasing the incidence of BRONJ remains to be determined.
In the patient group receiving oral bisphosphonates, the benefit
will be especially difficult to establish given the low incidence of
BRONJ.
Clinical presentation
A universally accepted term for this new condition has yet to be
established and this has resulted in some degree of confusion.
This complication has been referred to in the literature by sev-
eral acronyms including BRONJ (bisphosphonate-related os-
teonecrosis of the jaw), BRON (bisphosphonate-related os-
teonecrosis), BON (bisphosphonate osteonecrosis), BAONJ
(bisphosphonate-associated osteonecrosis of the jaw) and sim-
ply ONJ (osteonecrosis of the jaw). Based on the pattern of as-
sociation between bisphosphonate therapy and jaw necrosis
that has been established in numerous retrospective clinical
case studies, the American Association of Oral and Maxillofa-
cial Surgeons (AAOMS) has decided to adopt the term BRONJ
for this entity. 
Standardization of diagnostic criteria for this new clinical entity
is important in order to facilitate future clinical and epidemiolog-
ical research. In addition, a uniform definition for BRONJ will
serve to distinguish this new clinical entity from other delayed
intraoral healing conditions. Various organizations have pro-
posed clinical definitions for BRONJ, all of which are analogous
to each other. The AAOMS established a working definition for
BRONJ that is fairly concise and specific (43). Patients may be
considered to have BRONJ if all of the following three charac-
teristics are present: 1. Current or previous treatment with a
bisphosphonate; 2. Exposed, necrotic bone in the maxillofacial
region that has persisted for more than eight weeks; and 3. No
history of radiation therapy to the jaws. 
The American Society of Bone and Mineral Research (AS-
BMR) will make a recommendation for a provisional case defin-
ition for confirmed and suspected cases of bisphosphonate-as-
sociated osteonecrosis. A confirmed case is characterized by
an area of exposed bone in the maxillofacial region which did
not heal within 8 weeks in a patient who is or was exposed to a
bisphosphonate and did not have radiation therapy to the cran-
iofacial region. A suspected case was defined as an area of ex-
posed bone in the maxillofacial region that was present for less
than 8 weeks in a patient who is or was exposed to a bisphos-
phonate and did not have radiation therapy to the craniofacial
region. It is assumed that suspected cases are followed to de-
termine if they eventually meet the definition of a confirmed
case. The differential diagnosis of BRONJ should exclude oth-
er common clinical conditions which may include but are not
limited to alveolar osteitis, sinusitis, gingivitis/periodontitis,
caries, periapical pathology and temporomandibular joint disor-
ders. 
The patient history and clinical examination are the most sensi-
tive diagnostic tools for this condition. Areas of exposed and
necrotic bone may remain asymptomatic for weeks, months or
years and may result in pain or exposed maxillary or mandibu-
lar bone. These lesions are most frequently symptomatic when
surrounding tissues become inflamed or there is clinical evi-
dence of exposed bone. Signs and symptoms that may occur
before the development of clinically detectable osteonecrosis
include pain, tooth mobility, mucosal swelling, erythema, and
ulceration. These may occur spontaneously or more commonly
at the site of prior dentoalveolar surgery (Fig. 1). Most case se-
ries have described this complication at regions of previous
dental surgery (i.e. extraction sites) however exposed bone
has also been reported in patients with no history of trauma or
in edentulous regions of the jaw (Fig. 2). Intraoral and extraoral
fistula may develop when necrotic jaw bone becomes secon-
darily infected (Fig. 3). Some patients may also present with
complaints of altered sensation in the affected area as the neu-
rovascular bundle becomes compressed from the inflamed sur-
rounding bone. Chronic maxillary sinusitis secondary to os-
teonecrosis with or without an oral-antral fistula can be the pre-
senting symptom in patients with maxillary bone involvement
(Fig. 4). 
It has been observed that lesions are found more commonly in
the mandible than the maxilla (2:1 ratio) and more commonly in
areas with thin mucosa overlying bony prominences such as
tori, bony exostoses, and the mylohyoid ridge (20, 24, 27). The
size of the affected area can be variable and range from a non-
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healing extraction site to exposure and necrosis of the entire
jaw (Fig. 5). The area of exposed bone is typically surrounded
by inflamed erythematous soft tissue. Purulent discharge at the
site of the exposed bone will be present when these sites be-
come secondarily infected. 
Radiographic changes are typically not evident until there is
significant bone involvement or demineralization. Therefore,
panoramic and periapical radiographs may not reveal signifi-
cant changes in the early stages of osteonecrosis. Little or no
ossification at a previous extraction site may represent an ear-
ly radiographic sign. Early or late radiographic changes may
mimic classic periapical pathology, osteomyelitis, or in cancer
patients raise the suspicion of primary (myeloma) or metastat-
ic bone disease. If there is a strong clinical suspicion of
metastatic disease within the jaw and the diagnosis of such
will alter clinical treatment decisions, then a bone biopsy
should be considered. Otherwise, bone biopsies in these pa-
tients who have been exposed to intravenous bisphosphonate
therapy should not be performed given the potential for creat-
ing a non-healing bone wound. When there is extensive bone
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Figure 1 - A non-healing extraction site in a patient with a history of in-
travenous bisphosphonate exposure. 
Figure 2 - An area of exposed, necrotic bone that appeared sponta-
neously (i.e. no history of trauma) on the medial aspect of the mandible.
Figure 3 - Extra-oral draining fistula at the submental region of the jaw
in a patient with stage 3 BRONJ.
Figure 4 - Coronal CT of the right maxillary sinus demonstrating necro-
sis of the maxillary alveolar ridge and sinusitis.
Figure 5 - Resected right hemi-mandible in a patient with stage 3
BRONJ. Note the extensive amount of necrosis throughout the ramus
and body region of the mandible.
involvement, regions of mottled bone or sequestrum similar to
that of diffuse osteomyelitis are noted (Fig. 6). Widening of the
periodontal ligament space may also be noted radiographical-
ly. After prolonged exposure to the intravenous bisphospho-
nates, osteosclerosis of the bone may be noted radiographi-
cally, especially osteosclerotic lamina dura. In more advanced
stages of BRONJ, the osteolytic changes can extend to the in-
ferior border of the mandible and result in a pathologic fracture
(Fig. 7). 
Computerized tomography scans can provide more accurate 3-
dimensional information about the extent of the necrosis and is
often useful for planning surgical debridement procedures. How-
ever it has not proved helpful with early identification of this
process in asymptomatic individuals. Magnetic resonance imag-
ing (MRI) has the ability to detect marrow edema which may be
an early sign of bone ischemia and necrosis but it is associated
with a high rate of false positive results. Radionucleotide bone
scans are the most sensitive modality for detecting changes in
bone vascularity and may be helpful if vascular changes prove to
be part of the early phase of BRONJ. In general, all imaging
modalities have proved helpful in determining the extent of the
existing necrotic process but have yet to demonstrate any effica-
cy in assessing patients at risk for BRONJ. 
The microscopic examination of debrided specimens of ex-
posed bone will typically reveal necrotic bone with associated
bacterial debris and granulation tissue. 
Microbial cultures from areas of exposed bone will usually iso-
late normal oral microbes and therefore are not always helpful.
However in cases where there is extensive soft tissue involve-
ment, microbial culture data may define co-morbid oral infec-
tions and facilitate the selection of an appropriate antibiotic reg-
imen.
Staging
The presentation and symptomatology of BRONJ can vary in
patients despite similar disease processes, bisphosphonate
dosage regimens and treatment duration. A clinical staging
system (Tab. I) has been developed in order to more accurate-
ly categorize patients with BRONJ, direct rational treatment
guidelines and collect data to assess the prognosis in patients
who have used either intravenous (IV) or oral bisphosphonates
(27, 43). In a broad sense, patients can be categorized into
those at risk and those with established disease. Patients who
are considered “at risk” by the AAOMS criteria have no evi-
dence of exposed or necrotic bone but have been exposed to
either IV or oral bisphosphonates. The potency of the bisphos-
phonate used, the duration of exposure and dental surgery ap-
pear to be the main determinates in assessing the risk of de-
veloping BRONJ. 
Patients with stage 1 disease have exposed bone but are
asymptomatic. There is no evidence significant adjacent or re-
gional soft tissue inflammatory swelling or infection. It is possi-
ble that patients may have symptoms of pain prior to the devel-
opment of radiographic changes suspicious for osteonecrosis
or clinical evidence of exposed bone. Stage 2 disease is char-
acterized by exposed bone with associated pain, adjacent or
regional soft tissue inflammatory swelling or secondary infec-
tion. Patients with stage 3 disease have exposed bone associ-
ated with pain, adjacent or regional soft tissue inflammatory
swelling or secondary infection. Patients with pathologic frac-
ture, extra-oral fistula or radiographic evidence of osteolysis
extending to the inferior border are also considered stage 3.
The likelihood of a patient with stage 1 or 2 progressing to a
more advanced stage has not been determined but will certain-
ly be dependant on several variables, not the least of which is
the duration of bisphosphonate exposure and whether the pa-
tient is still receiving bisphosphonate therapy. 
In broad terms, managing patients with BRONJ can be very
challenging since most surgical and medical interventions do
not eradicate this process. In fact, except for those patients
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Figure 7 - Panoramic radiograph demonstrating a pathologic fracture of
the right parasymphysis region of the mandible in a patient with
metastatic breast and stage 3 BRONJ.
Figure 6 - Panoramic radiograph demonstrating a region of osteolysis
at the right mandibular angle region.
Table I - Clinical staging of BRONJ.
At risk category No apparent exposed/necrotic bone in patients who have been treated with either oral or intravenous bisphosphonates
Stage 1 Exposed/necrotic bone in patients who are asymptomatic and have no evidence of infection
Stage 2 Exposed/necrotic bone associated with infection as evidenced by pain and erythema in the region 
of the exposed bone with or without purulent drainage
Stage 3 Exposed/necrotic bone in patients with pain, infection, and one or more of the following: pathologic fracture, 
extra-oral fistula, or osteolysis extending to the inferior border
with stage 3 disease who require surgical resections for pallia-
tion, most surgical interventions have resulted in an increase in
the area of exposed bone. It is important for patients and clini-
cians to realize that a cure may not be a realistic expectation.
The goal of treatment for patients at risk of developing BRONJ
or who have active disease is to preserve the quality of life by
controlling pain, managing infection and preventing the devel-
opment of new areas of necrosis. This has to be balanced with
the oncologic management of the patient with osteolytic metas-
tases. 
The BRONJ treatment algorithms that have been published are
either a consensus of expert opinions or based on case series
data (27, 24, 27, 43). These management strategies have var-
ied according to the risk of developing BRONJ or the stage of
disease. Nonetheless, the main emphasis at this time is to min-
imize the risk of developing BRONJ. Although a small percent-
age of patients receiving bisphosphonates develop osteonecro-
sis of the jaw spontaneously, the majority of affected patients
experience this complication following simple dentoalveolar
surgery (i.e. extraction, dental implant placement or apical
surgery). Therefore, treatment strategies that optimize dental
health have been the main directive in managing patients who
will receive or are receiving bisphosphonate therapy. Consider-
ation has also been given to those patients who are about to
initiate bisphosphonate therapy and therefore assume a level
of risk at a future point in time. Their degree of risk will certainly
depend on the type of bisphosphonate and the duration of ex-
posure. For those patients with established BRONJ, treatment
is basically directed by the symptoms. Patients with stage 1
disease are by definition asymptomatic and therefore require
no intervention other than periodic oral rinses and close clinical
follow up. Otherwise, patient with symptomatic disease (stages
2 and 3) will require antibiotic therapy and/or surgical debride-
ment. All patients with established BRONJ are likely at high
risk of developing BRONJ at any future site of dentoalveolar
surgery and therefore should educated on the benefits of pro-
phylactic dental care and avoid extractions. 
Conclusion
Despite the strong clinical correlation between jaw necrosis
and bisphosphonate therapy, a definitive casual relationship
has yet to be established. Retrospective studies have estab-
lished an association but prospective clinical trials and basic
science research are needed to elucidate the pathogenesis of
this process and to more accurately define the clinical and
perhaps genetic risk factors. The efficacy of these agents in
treating and preventing the significant skeletal complications
associated with osteoporosis and bone metastases has had a
major positive impact for patients. A more complete under-
standing of BRONJ will allow clinicians to predict who will
benefit most from bisphosphonate therapy and to make more
accurate judgments about risk, prognosis, treatment selec-
tion, and outcome. 
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